Proton Beam Therapy Is Expanding From Research Hospitals Into Community Cancer Centres and the Single-Room System Made It Possible

The Precision That X-Ray Radiation Cannot Match

Proton beam therapy is a form of external beam radiation treatment that uses a beam of protons accelerated to between sixty and two hundred and fifty million electron volts to deliver radiation dose to tumour targets with a physical precision that conventional X-ray based radiation cannot achieve. The physical basis of protons' dosimetric advantage is the Bragg peak: protons deposit the majority of their energy at a specific depth in tissue determined by their initial energy, and deposit very little energy beyond that depth. X-rays, by contrast, deposit dose along their entire path through the patient, entering and exiting tissue with dose deposited throughout the beam path including in normal tissues beyond the tumour. The clinical consequence is that proton therapy can deliver a prescribed dose to the tumour target while reducing the dose to normal tissues adjacent to and beyond the target by proportions that in specific clinical situations produce measurable reductions in treatment toxicity and in radiation-induced secondary effects whose long-term clinical significance is greatest in paediatric patients whose treatment at young ages creates decades of time for radiation-induced complications to manifest. The paediatric cancer application accounts for approximately twenty-two percent of global proton therapy treatments and is the clinical segment whose toxicity reduction benefit from proton therapy's superior dose conformality is most clearly established and most widely endorsed by clinical evidence.

The global proton therapy market, valued at approximately $1.7 billion in 2026 and growing at over thirteen percent annually toward a projected $4 billion by 2033, reflects both the clinical value of proton therapy in appropriately selected patients and the technology's transition from exclusively large research hospital applications toward the community cancer centre and mid-sized hospital markets that the development of compact single-room proton therapy systems has opened. The original multi-room proton therapy facilities whose cyclotron or synchrotron particle accelerators and multiple gantry treatment rooms occupy the footprint of a small building and cost between $100 million and $200 million were accessible only to the largest academic medical centres and cancer institutes whose capital budgets and patient volumes could justify the investment. The single-room proton therapy system, whose integration of a compact superconducting cyclotron or synchrocyclotron with a single treatment room reduces the facility cost to $25 million to $50 million and the building footprint to dimensions that community hospitals can accommodate within existing or modestly expanded facilities, has fundamentally changed the potential market size for proton therapy by bringing it within the capital and space constraints of the hospitals where the majority of cancer patients receive their care.

IBA and the ProteusONE Commercial Standard

Ion Beam Applications is the Belgian particle accelerator and proton therapy company whose ProteusONE single-room proton therapy system has established the commercial benchmark for compact proton therapy. Its superconducting synchrocyclotron whose magnetic field of nine Tesla achieves the proton acceleration that would require a much larger conventional cyclotron in a magnet that fits in a room rather than occupying a building, integrated with a compact gantry and patient positioning system in a single-room configuration, has been installed in cancer centres across Europe, Asia, and North America whose patient volumes and capital budgets represent the mid-tier hospital market that multi-room proton therapy systems could not penetrate. IBA's February 2025 partnership with the Asian Institute of Gastroenterology in Hyderabad, India for a ProteusONE installation demonstrates the expansion of proton therapy into the Asian private hospital market whose quality-conscious patient population and growing cancer incidence create the commercial demand for advanced radiation oncology technology that India's urban private hospital sector is investing in.

Mevion Medical Systems' S250-FIT system, whose clinical investigation is assessing the system's ability to fit within existing radiation oncology departments without the dedicated building construction that conventional proton therapy installations require, represents the next commercial step in proton therapy accessibility. The ability to install a compact proton therapy system in a radiation oncology department that already has linear accelerator infrastructure, using the existing radiation bunker modifications rather than new construction, would reduce the capital and timeline barriers to proton therapy adoption at community hospitals to levels that the market's penetration of the addressable cancer patient population could reach the ten percent or greater of radiation oncology patients that clinical evidence suggests would benefit from proton therapy's dosimetric advantages over X-ray based treatment.

Pencil Beam Scanning and the Treatment Quality Revolution

The clinical quality of proton therapy delivery has improved substantially with the adoption of pencil beam scanning as the standard delivery technique replacing the older passive scattering approaches that shaped proton beams using physical scatterers and collimators. Pencil beam scanning delivers protons in a fine beam that scans across the tumour volume under magnetic control, depositing dose at each position according to the treatment plan's calculated prescription, with the ability to modulate dose at each beam position that allows the treatment planning system to optimise the three-dimensional dose distribution with a precision that passive scattering cannot achieve. The combination of pencil beam scanning delivery with intensity-modulated proton therapy treatment planning creates the proton therapy treatment quality that clinical comparisons with intensity-modulated X-ray radiation demonstrate the dose reduction to organs at risk whose clinical benefit in reducing treatment toxicity justifies the premium cost of proton therapy for patients whose anatomy places critical normal structures adjacent to their tumour targets.

Top 10 Companies in Proton Beam Therapy Systems Globally

1. IBA (Ion Beam Applications): Belgian proton therapy company with ProteusONE single-room and Proteus PLUS multi-room systems; its global installed base across Europe, Asia, and North America and its 2023 next-generation superconducting synchrocyclotron with twenty percent energy reduction create the proton therapy equipment market leader whose ProteusONE has defined the commercial single-room proton therapy standard.
2. Varian Medical Systems (Siemens Healthineers): US radiation therapy company with ProBeam 360 proton therapy system featuring pencil beam scanning and compact design; its 2024 ProBeam 360 system with fifty percent faster treatment delivery and its integration within Siemens Healthineers' comprehensive oncology portfolio create the radiation oncology platform whose proton therapy system leverages Siemens' global hospital relationships.
3. Mevion Medical Systems: US single-room proton therapy company with the S250-FIT system designed to fit in existing radiation oncology departments; its compact superconducting synchrocyclotron integrated directly onto the gantry arm eliminates the separate accelerator room that other proton therapy systems require, creating the most compact proton therapy installation footprint available commercially.
4. Hitachi: Japanese technology company with proton and carbon ion therapy systems for Asian and international markets; its synchrotron-based proton therapy systems and its carbon ion therapy capability create the Japanese proton therapy equipment manufacturer whose domestic market relationships and Asia-Pacific distribution create the regional leadership in the fastest-growing proton therapy geography.
5. ProNova Solutions: US proton therapy company with SC360 superconducting proton therapy system; its rotating gantry design and its focus on the community hospital market create the US single-room proton therapy competitor whose clinical programme development targets the market segment that IBA and Mevion pioneered.
6. Sumitomo Heavy Industries: Japanese heavy engineering company with proton therapy systems for the Japanese domestic and export markets; its synchrotron-based proton therapy technology and its long operational experience in Japanese proton therapy centres create the Japanese equipment manufacturer's proton therapy commercial position in a market whose domestic healthcare system has the highest per-capita proton therapy centre density globally.
7. Advanced Oncotherapy: UK proton therapy company developing the LIGHT linear accelerator-based proton therapy system that uses linac acceleration rather than cyclotron or synchrotron technology; its linac-based approach that modulates proton energy without the degrader that synchrocyclotron systems use creates the alternative accelerator technology whose size and cost advantages over cyclotron-based systems are the commercial proposition its development programme targets.
8. Mitsubishi Electric: Japanese electronics company with proton therapy system components and complete system integration capability; its synchrotron accelerator technology and its Japanese cancer centre relationships create the established Japanese proton therapy equipment supplier whose technology development supports both domestic Japanese hospital installations and export market growth.
9. ProTom International: US proton therapy company with the Radiance 330 proton therapy system using a compact synchrotron; its variable energy delivery capability that allows treatment at energies from prostate to intracranial targets without degraders and its smaller footprint relative to multi-room synchrotron installations create the compact synchrotron proton therapy commercial position.
10. Particle Therapy Co-Operative Group: International clinical research organisation for proton and particle therapy whose centre registry tracks global proton therapy facility development; its registry data showing over one hundred and twenty operating proton therapy centres globally in 2026 and over forty additional centres under construction quantifies the commercial expansion of proton therapy infrastructure that equipment manufacturers are supplying.